Iwona Skoneczna
Overview
Explore the profile of Iwona Skoneczna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gillessen S, Tombal B, Turco F, Choudhury A, Rodriguez-Vida A, Gallardo E, et al.
Eur Urol
. 2025 Jan;
87(3):285-288.
PMID: 39827019
Bone health is central to the management of patients with metastatic castration-resistant prostate cancer (mCRPC). International guidelines recommend giving a bone-protecting agent (BPA) to patients with mCRPC and bone metastases....
2.
Sigorski D, Wilk M, Gawlik-Urban A, Salek-Zan A, Kiszka J, Malik M, et al.
Front Oncol
. 2023 Apr;
13:1108937.
PMID: 37077831
Background: Abiraterone acetate (ABI) and Enzalutamide (ENZA) are second-generation hormone drugs that show breakthrough activity in post-chemotherapy, metastatic castration-resistant prostate cancer (mCRPC). The leading oncological and urological guidelines indicate both...
3.
Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, et al.
Eur J Cancer
. 2023 Apr;
185:178-215.
PMID: 37003085
Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to...
4.
Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, et al.
Eur Urol
. 2022 Dec;
83(3):267-293.
PMID: 36494221
Background: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety...
5.
Wilk M, Wasko-Grabowska A, Skoneczna I, Szczylik C, Szmit S
Cancer Control
. 2022 Nov;
29:10732748221140696.
PMID: 36447439
Background: Abiraterone acetate (AA) is a drug used in advanced prostate cancer. However, known clinical factors with predictive and prognostic value are scarce. This study evaluated cardiovascular (CV) factors and...
6.
Gillessen S, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, et al.
Eur Urol
. 2022 Apr;
82(1):115-141.
PMID: 35450732
Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021...
7.
Turco F, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, et al.
Eur Urol
. 2022 Apr;
82(1):e18-e19.
PMID: 35440417
No abstract available.
8.
Turco F, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, et al.
Eur Urol
. 2022 Apr;
82(1):6-11.
PMID: 35393158
Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive...
9.
Initial Experience of Clinical Use of [Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study
Cwikla J, Roslan M, Skoneczna I, Kempinska-Wrobel M, Maurin M, Rogowski W, et al.
Pharmaceuticals (Basel)
. 2021 Nov;
14(11).
PMID: 34832889
Numerous different molecules of prostate-specific membrane antigen (PSMA) ligands are used to detect prostate cancer (PCa); most approaches utilize gallium PET and a few reports describe the role of SPECT/CT....
10.
Wilk M, Wasko-Grabowska A, Skoneczna I, Szmit S
Front Oncol
. 2021 Apr;
11:664741.
PMID: 33869068
Background: Abiraterone acetate (ABI) therapy improves overall survival in metastatic prostate cancer (PC) patients; however, this effect may be diminished by concurrent comorbidities. We aimed to evaluate the influence of...